Background: Proto-oncogene MYC has been indicated to promote progression of many cancers. However, prognostic and clinicopathological significance of MYC in breast cancer need further evaluation.
INTRODUCTION
Nearly 2 million new breast cancer cases are diagnosed each year from all around the world and account for the first or second leading cause of cancer death in female from developing and developed country respectively [1, 2] . In addition, breast cancer is a heterogeneous disease with a variety of subtypes and molecular markers and displays multiple clinical outcomes and histological characteristics [3] . At present, we use systemic therapies to improve the survival of breast cancer patients, including surgical treatment, chemotherapy, endocrine therapy or immunotherapy [4] . Unfortunately, some effective therapies are hampered by existing biomarkers and the prognosis of breast cancer patients still doesn't meet our expectations. Thus, searching new biomarkers and therapeutic targets is very significant for patients with invasive breast cancer [5] . New and more effective biomarkers should be explored to predict prognosis and make best therapeutic choice [6] .
Proto-oncogene MYC, also named c-Myc and bHLH transcription factor, is an indispensable signal core in a variety of biological processes that support the growth of various types of cancer, such as ovarian cancer, endometrial cancer, breast cancer and so on [7, 8] . MYC regulates the expression of many target genes and non-coding that activate or suppress cell cycle progression, apoptosis, differentiation and control mechanisms of drug resistance [3, 9] . In breast cancer, lots of studies have investigated the significance of MYC. Some studies display positive relationships between MYC overexpression and prognostic/ clinicopathological outcome [10] [11] [12] , while others show contrary results [13] [14] [15] . In the past 20 years, there was only one published meta-analysis about MYC and prognostic and clinicopathological significance of breast cancer in 2000 [16] . Though it provided some information, the detection method of MYC expression was very different from that today and the number of included studies with prognosis of breast cancer patients was small. Thus, we need new more systematic studies to acquire high quality and relatively reliable data of prognostic and clinicopathological significance of MYC to stratify breast cancer patients who would benefit from MYC targeted therapy and provide evidence to prospective treatment.
RESULTS

Description of included studies
We searched 2167 records in total and then selected 124 candidate studies. After further screening, there were 87 studies excluded because of cell experiment, animal specimen, breast angiosarcoma and male patients. Among the remaining studies, three studies [17] [18] [19] used the same patient cohorts of other three studies [15, 20, 21] and we chose the high quality studies among them. Then two studies with scores less than 4 and three studies with invalid data were excluded. Ultimately, 29 studies (36 cohorts) were included and the detailed processes of literature search and study selection were shown in Figure 1 .
There were 29 studies (36 cohorts) with 12621 breast cancer patients in total involved in our meta-analysis. Among them, 11 studies (16 cohorts) with 5390 patients were available for RFS/DFS survival data and 7 studies (8 cohorts) with 2672 patients were available for OS survival Figure 1 : Selection of studies. Flow chart showed selection of the studies in the meta-analysis. www.impactjournals.com/oncotarget data. 14 (48.3%) studies used FISH method to detect the expression of MYC and the remaining articles applied IHC, qPCR, Genechip, dPCR, SOA and hybridization respectively. All included articles were retrospective. We used the Newcastle-Ottawa quality assessment scale to assess their quality and scores of included studies ranged from 5 to 8 with a mean of 6.966 (Table 1 ).
Data synthesis: clinicopathological features
Our meta-analysis showed that overexpression of MYC significantly correlated to large tumor size, OR=1. (Figure 2A ). In addition, results of subgroup analysis according to ethnicity ( Figure 2B )/ technique ( Figure 2C )/ data sources ( Figure 2D ) showed that high MYC expression was associated with poor DFS/RFS in Asian and non-Asian subgroups, FISH and other technique subgroups, and two different data source subgroups. (Table 3) Data synthesis: overall survival OS was analyzed in 7 articles (8 cohorts) with 2672 patients. Results showed that high MYC expression was associated with poor OS, HR=3.029 (2.385-3.847) ( Figure 3A ). In addition, results of subgroup analysis by ethnicity ( Figure 3B )/ technique ( Figure 3C )/ data sources ( Figure 3D ) showed high MYC expression was associated with poor OS in all ethnicity, technique, data source subgroups respectively (Table 3) .
Publication bias
We applied Begg's /Egger's test and their funnel plot to assess publication bias. Analysis results of Begg's /Egger's test for DFS/RFS and OS were 0.087/ 0.029 ( Figure 4A and 4C ) and 0.322/0.124 ( Figure 4B and 4D) respectively.
Sensitivity analysis
After removing each study at a time, each HR result was shown in Figure 5A -5B. Removal of each study did not change HR significantly both for the DFS/RFS and OS analysis. Furthermore, we used trim and fill method to evaluate the sensitivity of results again. After trimming and filling, the HR tendency of OS did not change ( Figure  6B and 6D) , however, the HR trend of DFS/RFS was reversed ( Figure 6A and 6C ).
DISCUSSION
The proto-oncogene MYC, which encodes a nuclear phosphoprotein transcription factor, plays an important role in various cellular biological processes, such as cell invasion, metabolism, differentiation, proliferation, drug resistance [22] . A lot of clinical researches published before have investigated MYC expression and related signal pathway in breast cancer cells and patients, and discovered strong correlation between MYC overexpression and breast cancer progression [3, 9] . Our results showed that high MYC expression was associated with worse DFS/RFS and OS for breast cancer patients. Besides, MYC overexpression was related to tumor size of more than 2 cm, high histologic grade, lymph node metastasis, negative ER status, negative PR status, positive Ki67 expression. Thus, MYC could be regarded as a potential biomarker and therapeutic target for breast cancer patients.
In our meta-analysis, DFS/RFS displayed moderate heterogeneity. Then subgroup analysis was performed and we found that technique was the origin of heterogeneity. HR of FISH and other technique subgroups in 7 studies (8 cohorts) displayed a poor prognosis of high MYC expression in breast cancer patients, however, the technique of IHC and Genechip (5 studies/ 8 cohorts) showed a negative prognosis of MYC overexpression. These opposite results were mainly because that IHC detected the level of protein, but FISH detected the level of DNA. With regard to subgroup of Genechip, one study (two cohorts) used 2 different cohorts of endocrine therapy but not chemotherapy treated patients and chemotherapy treated patients [23] . This would lead to heterogeneity and got different results. The other subgroups of DFS/RFS, ethnicity and Data source, displayed the same significance of HR excepting for Mix of ethnicity. The reason may be the same as that in Genechip subgroup. The results of OS displayed mild heterogeneity. Though all subgroups of OS showed a positive significance between poor prognosis and high MYC overexpression, further subgroup analysis of OS showed the heterogeneity was also conducted from different technique, the reasons of heterogeneity in technique subgroup were explained as what we discussed above.
Besides, Begg's/Egger's test showed there was no evidence of publication bias for OS in regard to high MYC expression, however, Egger's test displayed, Begg's test not, some evidence of publication bias in DFS/RFS group. Though both HR results of DFS/RFS and OS showed there was significant between high MYC expression and DFS/RFS/ OS, further analysis of trim and fill method in DFS/RFS showed a reversed result. It indicated that future new studies about this would change in HR result of DFS/ RFS. This might be mainly because that the heterogeneity of different technique resulted in this.
Some articles studied the relationships between MYC amplification/overexpression and hormone receptors [17, 24] and found that MYC amplification/overexpression was more frequent in breast cancer without ER or PR expression, that could be used as a potential target in breast cancer of negative hormone receptors. Our meta-analysis also displayed that high MYC expression related to the negative ER and PR. Interestingly, there was no statistical significance of high MYC expression in TNBC and HER- Of course, there are still limitations in our metaanalysis. In the first place, identifications of high MYC expression in included studies aren't exactly the same and different techniques might be the source of heterogeneity and lead to contrary results. Besides, Egger's test of DFS/ RFS showed there was statistical significance and further analysis of trim and fill method in DFS/RFS displayed a reversed result. It means, in the future new studies might change our DFS/RFS results of meta-analysis. Although Begg's and Egger's test of OS showed that there was no statistical significance. We should cautiously understand these results, because just available HR or K-M survival curves were included, and technique was still the source of heterogeneity in OS.
In short, this meta-analysis implies that high MYC expression in breast cancer is related to poor prognosis of patients, especially to patients with negative ER and PR. And more studies about the relationships between DFS/ RFS and MYC over expression need be done in the future, different techniques of detecting MYC might lead to discrepancy results. Combination therapy of MYC signal pathway inhibitors would improve clinical outcomes of breast cancer patients, especially for patients with negative hormone receptors. 
MATERIALS AND METHODS
Literature search
Our meta-analysis was processed according to PRISMA guidelines. Studies were extracted by searching PubMed and EMBASE databases commencing 1997 through July, 2017 by using the search words "MRTL OR MYCC OR c-Myc OR bHLHe39 OR MYC AND breast cancer". We firstly scanned titles and abstracts to exclude unrelated and review studies. Then we made finally decision to choose useful studies by reading the full text. Associated references from included studies were manually searched to add relevant articles.
Inclusion and exclusion
All of our included studies satisfied the following inclusion criteria: 1) diagnosis of breast cancer was proven by pathologists; 2) investigating the relationships between high MYC expression and DFS/RFS, OS, or clinicopathological data in breast cancer patients; 3) provided the data of HR and 95% CIs, or Kaplan-Meier survival curves of DFS/RFS or OS, which provided us available data to extract HR and 95% CI. 4) NOS score ≥ 5. Exclusion criteria: 1) no available data of prognostic or clinicopathological information and the data could not be applied to calculate from Kaplan-Meier survival curve; 2) NOS score ≤ 4.
Data extraction
Two reviewers (Jingkun Qu and Xixi zhao) searched and evaluated the studies independently. The following information was extracted from every included study, including first author name, published year, breast cancer patients source, type of patients, age, patients number, detecting technique, high MYC expression (%), followup time, DFS/RFS/OS and other clinicopathological features. If the univariate and multivariate analysis were both available, the multivariate results were chosen. If the above information was not found, we used "NA (not available)" to mark.
Quality of the studies
We applied the Newcastle-Ottawa Scale to evaluate the quality of every included study [26] .
Statistical analysis
HR and 95% CIs were applied to investigate the relationships between high MYC expression and DFS/ RFS/OS. If survival information was only available in the form of figures, we scanned Kaplan-Meier survival curves through Engauge Digitizer version 4.1 (free Engauge Digitizer could be acquired on http://sourceforge.net) and recovered survival information of HR and 95%CI [27, 28] . Information of clinicopathology was extracted in available studies to calculate OR by Stata. The analysis of heterogeneity, publication bias and sensitivity were describe as before [6] . Statistical analysis was processed by Stata 14.0 (Stata Corporation, College Station, TX).
